Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
IJRM-Iranian Journal of Reproductive Medicine. 2014; 12 (6): 415-420
in English | IMEMR | ID: emr-159474

ABSTRACT

Embryo transfer to a developed endometrium is an important prognostic factor in frozen-thawed embryo transfer cycle outcome. Vaginal estrogen, such as Vagifem vaginal tablets and Premarin vaginal cream, is a regimen used for the patients with refractive endometria. Our objective was to compare the effects of Vagifem and Premarin on the endometrial thickness of the patients with refractive endometria. In this randomized clinical trial, 30 patients with refractive endometria in frozen-thawed embryo transfer cycles received Vagifem vaginal tablets and 30 women received Premarin vaginal cream. Endometrial thickness was measured on the 14th day of drug administration. Comparing the endometrial thicknesses of the two groups showed that the endometria of the Vagifem group was significantly thicker than that of the Premarin group [5.93 +/- 0.38 vs. 6.74 +/- 0.32; p<0.001]. Vagifem is superior to Premarin in induction of endometrial thickness in frozen-thawed embryo transfer cycles in the patients with refractive endometria

2.
IJI-Iranian Journal of Immunology. 2014; 11 (1): 13-20
in English | IMEMR | ID: emr-157626

ABSTRACT

Miscarriage is a common phenomenon complicating more than half of pregnancies. Recurrent Pregnancy Loss [RPL] is defined as three or more pregnancies lost before the twentieth week of gestation. It is believed that abnormality in maternal immune reaction to fetus and sharing of HLA antigens might be associated with RPL. To investigate the effect of HLA-DRB1 sharing between the couples with recurrent pregnancy loss on the pregnancy outcome after leukocyte therapy. Sixty primary RPL women who were immunized and followed after therapy [30 successful and 30 unsuccessful] and their husbands formed the cases of this study. In addition, one hundred healthy women were considered as the controls. HLA-DRB1 genotypes of all the cases and controls were checked by PCR-SSP method. HLA typing indicated that the prevalence of HLA-DRB1 sharing [defined as at least one allele sharing] between the couples with unsuccessful outcomes was significantly higher compared to those with successful outcomes [63.3% vs. 23.3%, p<0.004]. Moreover, HLA DRB1*07:01 allelic group was significantly more frequent in the patients with unsuccessful outcome compared to the controls [18.3% vs. 8%, p<0.04]. Our results confirmed the role of HLA sharing in RPL and revealed that HLA-DRB1 typing may be a valuable prognostic factor for the leukocyte therapy outcome


Subject(s)
Humans , Female , HLA Antigens/immunology , Histocompatibility Testing , Pregnancy Outcome , Leukocytes, Mononuclear/immunology , Family Characteristics , Alleles , Genotype
SELECTION OF CITATIONS
SEARCH DETAIL